Land: Kanada
Sprache: Englisch
Quelle: Health Canada
MORPHINE SULFATE
PALADIN LABS INC.
N02AA01
MORPHINE
20MG
DROPS
MORPHINE SULFATE 20MG
ORAL
25ML/100ML
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0104545002; AHFS:
CANCELLED POST MARKET
2018-09-18
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N STATEX ® morphine sulfate Oral Drops – 20 and 50 mg/mL Suppositories – 5, 10, 20 and 30 mg Oral Syrup – 1, 5 and 10 mg/mL Tablets – 5, 10, 25 and 50 mg Opioid Analgesic Paladin Labs Inc. 100 Alexis Nihon Blvd., Suite 600 St-Laurent, Quebec H4M 2P2 Date of Preparation: December 4, 1985 Date of Revision: April 5, 2018 Version: 5.0 Submission Control No: 211412 _ _ _STATEX_ _®_ _ _ _Page 2 of 35_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION .....................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................14 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 STORAGE AND STABILITY ..........................................................................................21 SPECIAL HANDLING INSTRUCTIONS .......................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................22 PART II: SCIENTIFIC INFORMATION ...............................................................................24 PHARMACEUTICAL INFORMATION ..........................................................................24 DETAILED PHARMACOLOGY ................................ Lesen Sie das vollständige Dokument